Sleep apnea ‘ups insulin resistance’

Washington, May 18 (ANI): Researchers from the University of Pittsburgh Medical Center claim that sleep apnea could cause metabolic changes that increase insulin resistance.

The intermittent hypoxia associated with sleep apnea causes a distinct drop in insulin sensitivity in mice, even though chronic hypoxia, such as that associated with high altitude, did not.

The research will be reported at the ATS 2010 International Conference in New Orleans.

To determine whether intermittent hypoxia (IH) and chronic hypoxia (CH) would have different metabolic effects, Dr. Lee and colleagues fitted adult male mice with arterial and venous catheters for continuous rapid blood monitoring of glucose and insulin sensitivity.

They then exposed the mice to either seven hours of IH, in which treatment, oxygen levels oscillated, reaching a low of about 5 percent once a minute, or CH, in which they were exposed to oxygen at a constant rate of 10 percent, and compared each treatment group to protocol-matched controls.

When compared to the control group, the IH mice demonstrated impaired glucose tolerance and reduced insulin sensitivity; the CH group, however, showed only a reduction in glucose tolerance but not insulin sensitivity compared to controls. “Both intermittent hypoxia and continuous hypoxia exposed mice exhibited impaired glucose tolerance, but only the intermittent hypoxia exposed animals demonstrated a reduction in insulin sensitivity,” said Euhan John Lee, M.D., a fellow at the Medical Center.

“The intermittent hypoxia of sleep apnea and the continuous hypoxia of altitude are conditions of hypoxic stress that are known to modulate glucose and insulin homeostasis. Although both forms of hypoxia worsen glucose tolerance, this research demonstrated that the increase in insulin resistance that accompanies intermittent hypoxia, or sleep apnea, is greater than that seen with continuous hypoxia, or altitude,” explained Dr. Lee.

The specific finding that intermittent, but not continuous, hypoxia induced insulin resistance was not expected.

Increased generation of reactive oxygen species, initiation of pro-inflammatory pathways, elevated sympathetic activity, or upregulation of insulin counter-regulatory hormones in IH may contribute to the greater development of insulin resistance in those mice versus those exposed to continuous hypoxia.

“As sleep apnea continues to rise with the rate of obesity, it will be increasingly important to understand both the independent and interactive effects of both morbidities on the development of metabolic disorders. This research demonstrated that intermittent hypoxic exposure can cause changes in insulin sensitivity and insulin secretion, which may have important consequences in metabolically vulnerable diabetic patients who present with co-morbid sleep apnea,” said Dr. Lee. (ANI)

‘Experienced’ female lizards more likely to be courted by males

Washington, May 15 (ANI): Female sagebrush lizards with greater courtship experience tend to attract greater attention from their male counterparts, according to a recent study.

For the study, Mayte Ruiz, Zachary M. Beals, and Emilia P. Martins, collected 13 male and 26 female sagebrush lizards from the San Gabriel Mountains of Southern California and housed them in terraria at Indiana University, Bloomington.

During a two-week test period, half of the female lizards were assigned at random to a low-courtship treatment group that received one visit from a robotic male lizard every other day, while the other female lizards were placed in a high-courtship group that saw the robotic male lizard four times daily.

The researchers wanted to see whether the amount of female courtship experience influences male sagebrush lizards’ behaviour.

“Repeated male courtship may be beneficial to males if increasing female exposure to courtship displays advances reproductive state,” wrote the researchers.

This also may help female lizards produce more fertilized eggs and breed earlier and more often.

After the two weeks of robotic lizard visits, a live male lizard was place in each female lizard’s terrarium for 30 minutes.

The researchers paired each male sequentially with two females—one from the low-courtship group and one from the high-courtship group.

“In our study, male lizards distinguished between females that had received more previous courtship and those that had received less, directing more tongue-flicks and moving more often toward females that had greater courtship experience than when placed with females that received few displays,” wrote the researchers.

“Although females did not differ in behavioral response due to display treatment, males may detect differences in physiological state of the female and respond accordingly,” they added.

They note that additional research is needed to determine physiological differences between females with varied courtship experience.

The researchers also note that their study “used a robotic lizard to create differences between females that were not detectable to human observers, and an assay of male behaviour to detect those differences.”

This shows how robotic stimuli can help manipulate animals in a controlled way for research purposes, they write.

The study has been published in the June 2010 issue of Herpetologica. (ANI)

‘Experienced’ female lizards more likely to be courted by males

Washington, May 15 (ANI): Female sagebrush lizards with greater courtship experience tend to attract greater attention from their male counterparts, according to a recent study.

For the study, Mayte Ruiz, Zachary M. Beals, and Emilia P. Martins, collected 13 male and 26 female sagebrush lizards from the San Gabriel Mountains of Southern California and housed them in terraria at Indiana University, Bloomington.

During a two-week test period, half of the female lizards were assigned at random to a low-courtship treatment group that received one visit from a robotic male lizard every other day, while the other female lizards were placed in a high-courtship group that saw the robotic male lizard four times daily.

The researchers wanted to see whether the amount of female courtship experience influences male sagebrush lizards’ behaviour.

“Repeated male courtship may be beneficial to males if increasing female exposure to courtship displays advances reproductive state,” wrote the researchers.

This also may help female lizards produce more fertilized eggs and breed earlier and more often.

After the two weeks of robotic lizard visits, a live male lizard was place in each female lizard’s terrarium for 30 minutes.

The researchers paired each male sequentially with two females—one from the low-courtship group and one from the high-courtship group.

“In our study, male lizards distinguished between females that had received more previous courtship and those that had received less, directing more tongue-flicks and moving more often toward females that had greater courtship experience than when placed with females that received few displays,” wrote the researchers.

“Although females did not differ in behavioral response due to display treatment, males may detect differences in physiological state of the female and respond accordingly,” they added.

They note that additional research is needed to determine physiological differences between females with varied courtship experience.

The researchers also note that their study “used a robotic lizard to create differences between females that were not detectable to human observers, and an assay of male behaviour to detect those differences.”

This shows how robotic stimuli can help manipulate animals in a controlled way for research purposes, they write.

The study has been published in the June 2010 issue of Herpetologica. (ANI)

Exercise beats shockwaves for chronic shoulder pain

London, Sept 16 (ANI): Supervised exercise helps ease chronic shoulder pain better than sound shockwave treatment, a new study suggests.

In the study, published in the online British Medical Journal, team of researchers based in Oslo, Norway compared the effectiveness of radial extracorporeal shockwave treatment (low to medium energy impulses delivered into the tissue) with supervised exercises in patients with shoulder pain.

The research involved 104 men and women aged between 18 and 70 years.

Participants were randomised to receive either radial extracorporeal shockwave treatment (one session weekly for four to six weeks) or supervised exercises (two 45 minute sessions weekly for up to 12 weeks).

Both groups were similar at the start of the study with regard to age, education, dominant arm affected and pain duration.

All patients were monitored at six, 12 and 18 weeks and were advised not to have any additional treatment except analgesics (including anti-inflammatory drugs) during the follow-up period. Pain and disability were measured using a recognised scoring index.

After 18 weeks, 32 of patients in the exercise group achieved a reduction in shoulder pain and disability scores compared with 18 in the shockwave treatment group.

More patients in the exercise group returned to work, while more patients in the shockwave treatment group had additional treatment after 12 weeks, suggesting that they were less satisfied.

The authors conclude: “Supervised exercises were more effective than radial extracorporeal shockwave treatment for short term improvement in patients with subacromial shoulder pain.” (ANI)

Nerve pain pill found effective in treating hot flashes

Washington, May 16 (ANI): A pill used to treat nerve pain has been found effective in treating hot flashes in women, claim Mayo Clinic researchers.

They have found that pregabalin decreased hot flash severity and frequency about 20 percent more than did a placebo.

Pregabalin has been found to offer about the same benefit as gabapentin, an older, related drug, as well as newer classes of antidepressants.

“Hot flashes are a major problem in many women, and for those who opt not to take hormonal therapies or antidepressants, pregabalin appears to be another treatment option,” said the study’s lead author, Charles Loprinzi, M.D., a medical oncologist at the Mayo Clinic in Minnesota.

Women who use pregabalin only need to take two pills a day, versus three for gabapentin, he added.

Gabapentin and a variety of antidepressants are commonly prescribed for treatment of hot flashes and pregabalin is a newer version of gabapentin.

Dr. Loprinzi and colleagues set up a 207-participant study conducted by the North Central Cancer Treatment Group (NCCTG). Patients getting pregabalin started off with lower doses which were increased weekly to the eventual full dose.

The researchers found that for the 163 patients both doses of pregabalin reduced hot flashes to about the same degree, but that toxicities, such as cognitive dysfunction, were increased at the higher dose.

After six weeks of treatment, women receiving pregabalin showed 65 percent decrease in hot flashes compared to 50 percent decrease in those receiving placebo.

“All in all, this study demonstrates that we have another agent to add to the list of medications that offer benefit against hot flashes, even in women using anti-estrogen therapies,” said Dr. Loprinzi .

The findings were presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). (ANI)

Early retroviral use beneficial for AIDS patients with serious complications

Washington, May 16 (ANI): Early retroviral use can significantly benefit AIDS patients with serious complications, suggest researchers.

Most patients don’t seek medical attention until they have a serious AIDS-related condition.

The research team from Stanford University School of Medicine showed that AIDS patients can reduce complications risk by half if they get antiretroviral treatment early on.

“This study shows that it is life-saving to treat those persons with antiretroviral drugs while they are still in the hospital. The results of this study will change practices throughout the world,” said Dr Mitch Katz, San Francisco’s director of health, who was not involved in the study.

Dr Andrew Zolopa, associate professor of infectious diseases and geographic medicine at Stanford and first author of the study said that growing number of the patients, particularly minorities, youth, injection-drug users and those in poor rural areas, are being diagnosed late in the disease process when they’ve already developed life-threatening conditions.

“A lot of people wait, thinking, ‘Let’s get the patient out of acute crisis, and then we’ll deal with the underlying HIV infection later,’” said Zolopa.

“But that answer is wrong. If we’re more aggressive with HIV drugs, we can reduce AIDS-related complications and death by 50 percent. It’s a substantial clinical benefit,” he added.

The study involved 262 patients at 39 sites across the United States, from Puerto Rico to Seattle. They all had one or more opportunistic infection, with the most common ones being pneumocystis jirovecii pneumonia, cryptococcal meningitis and serious bacterial infections.

They found that in patients treated early, there were 20 (14.2 percent) who died or developed another significant AIDS-related complication, compared with 34 patients in the deferred group who died or suffered a new complication.

In addition, the patients in the early treatment group saw a much swifter recovery of their immune systems.

According to Zolopa, the study results probably provide some guidance for patients in developing countries, though each country would have to determine its own strategy for initiating ARVs in patients with advanced AIDS.

The study appears in the online journal PLoS-ONE. (ANI)

Early retroviral use beneficial for AIDS patients with serious complications

Washington, May 16 (ANI): Early retroviral use can significantly benefit AIDS patients with serious complications, suggest researchers.

Most patients don’t seek medical attention until they have a serious AIDS-related condition.

The research team from Stanford University School of Medicine showed that AIDS patients can reduce complications risk by half if they get antiretroviral treatment early on.

“This study shows that it is life-saving to treat those persons with antiretroviral drugs while they are still in the hospital. The results of this study will change practices throughout the world,” said Dr Mitch Katz, San Francisco’s director of health, who was not involved in the study.

Dr Andrew Zolopa, associate professor of infectious diseases and geographic medicine at Stanford and first author of the study said that growing number of the patients, particularly minorities, youth, injection-drug users and those in poor rural areas, are being diagnosed late in the disease process when they’ve already developed life-threatening conditions.

“A lot of people wait, thinking, ‘Let’s get the patient out of acute crisis, and then we’ll deal with the underlying HIV infection later,’” said Zolopa.

“But that answer is wrong. If we’re more aggressive with HIV drugs, we can reduce AIDS-related complications and death by 50 percent. It’s a substantial clinical benefit,” he added.

The study involved 262 patients at 39 sites across the United States, from Puerto Rico to Seattle. They all had one or more opportunistic infection, with the most common ones being pneumocystis jirovecii pneumonia, cryptococcal meningitis and serious bacterial infections.

They found that in patients treated early, there were 20 (14.2 percent) who died or developed another significant AIDS-related complication, compared with 34 patients in the deferred group who died or suffered a new complication.

In addition, the patients in the early treatment group saw a much swifter recovery of their immune systems.

According to Zolopa, the study results probably provide some guidance for patients in developing countries, though each country would have to determine its own strategy for initiating ARVs in patients with advanced AIDS.

The study appears in the online journal PLoS-ONE. (ANI)

Exercise may benefit patients with mild to moderate OSA

Washington, May 7 (ANI): People suffering from mild to moderate form of obstructive sleep apnea (OSA) may benefit from certain tongue and pharyngeal exercises, according to a study.

“It was commonly thought among doctors that strengthening and toning oropharyngeal muscles would have no benefit to the patient during sleep, but a recent study showed that didgeridoo playing helped decrease snoring and OSA. This was a change of paradigm, and indicated that not everything you do during the day is lost during sleep,” said Dr. Geraldo Lorenzi-Filho.

During the study, the researchers investigated the effects of exercises on the symptoms of OSA in the first randomised, controlled study to do so. Thirty-one recently-diagnosed patients were evaluated for OSA severity using polysomnography.

Snoring frequency and intensity, daytime sleepiness and sleep quality were assessed using self-reports and validated questionnaires.

The subjects were the randomized to two groups-the exercise group and the control group. Each of the 16 individuals in the exercise group underwent a daily and weekly regimen of tongue and pharyngeal exercises.

There was also a control group of 15 individuals, who underwent a sham treatment regimen involving deep breathing and nasal lavage with a saline solution.

After three months, there were no significant changes to OSA symptoms in the control group, but the treatment group showed significant improvements in lowest oxygen saturation levels in blood, subjective sleepiness, snoring symptoms and quality of sleep scores.

The researchers said while there were no changes in abdominal circumference in either group, neck circumference decreased significantly in the treatment group with no concomitant changes in body mass index.

“These data suggest that the exercises were able to promote remodeling of the upper airways,” said Dr. Lorenzi-Filho.

Overall, the treatment groups showed a 40 percent decrease in OSA severity, with 10 the 16 patients who had originally been classified as having moderate OSA being reclassified as having either mild (eight) or no OSA (two).

“This was nearly two thirds of the treatment group, whereas none of the control group were reclassified with a milder disease. This indicates to us that these exercises have significant potential to improve symptoms in sufferers of OSA,” said Dr. Lorenzi-Filho.

“The muscles of the upper airways are extremely complex and the mechanisms leading to OSA are far from being well understood. A strong muscle may be working on the wrong direction and not necessarily helping to open the airways. The overall set of exercises we tested target the correct physiology of the upper airway and should promote remodeling of the upper airways,” said Dr. Lorenzi-Filho.

The researchers say that the evidence supports that certain exercises do, in fact, aid in remodelling the upper airways in such a way as to reduce OSA symptoms.

Dr. Lorenzi-Filho acknowledges that work is just beginning in this exciting area of research.

“How exactly these exercises work? Do we need all of them or just a few? Do different patients need different set of exercises? What are the exact mechanisms leading to upper airway obstruction?” he asked.

“The answer is we don’t know, but these are some of the possible future areas of research,” he said.

The study has been published in the American Journal of Respiratory and Critical Care Medicine. (ANI)

Novel nasal device highly effective in chronic rhinosinusitis treatment

Washington, Apr 18 (ANI): A new nasal delivery technology with fluticasone, developed by OptiNose, has been found effective in treating chronic rhinosinusitis in a Phase II trial.

Chronic rhinosinusitis (CRS) is a common disease that severely reduces a patient’s quality of life, and has few effective treatments currently available.

OptiNose’s breath-actuated, bi-directional nasal delivery technology significantly improves delivery to the target sites deep into the nose where the openings to the sinuses are located, which is considered essential to achieving clinical effects in CRS with topical treatments.

The study was conducted at the AMC in Amsterdam, Holland with Professor Wytske Fokkens as the principal investigator.

The researchers found that patients in the active treatment group experienced significant improvements in nasal symptoms, nasal discomfort and sense of smell.

The patients also reported a highly significant and progressive reduction in nasal swelling.

By using the OptiNose delivery device, patients self-administered fluticasone propionate 400 ug or placebo twice-daily at home over a 12-week period.

After the endoscopic assessment of the nasal mucosa, the researchers found a highly significant and progressive improvement to a normal state in the actively treated group.

At the post-study examination, 30 percent had a normal ENT-examination and peak nasal inspiratory flow and rhinosinusitis outcome measures were also significantly improved.

MR imaging before and after treatment showed significant improvement compared to baseline.

“We are extremely pleased with the effectiveness of our treatment for chronic rhinosinusitis”, said ENT-specialist Dr. Per Djupesland, the study’s co-author.

The study was presented at the Rhinology World conference in Philadelphia. (ANI)

Now, premature ejaculation spray that delays orgasm 6 times longer than normal

Washington, Apr 7 (ANI): Science is trying its level best to improve people’s sex lives -and the latest offering from scientists is a spray which helps men last six times longer in bed.

Developed by British doctors, the treatment – used five minutes before sex – can extend love-making time from seconds to almost four minutes.

The study has been published in the April issue of BJU International.

To reach the conclusion, three hundred men with clinically diagnosed lifelong premature ejaculation (PE) from 31 centres in the UK, Czech Republic, Hungary and Poland, were randomised into two groups.

Two hundred used the PSD502 spray, which contains 7.5mg of lidocaine and 2.5mg of prilocaine, and 100 used a placebo spray with no active ingredients.

Every time they had intercourse during the three-month study period, each couple measured the time from vaginal penetration to ejaculation with a stopwatch.

The men were asked to abstain from sexual activity or masturbation for 24 hours before each recorded encounter.

The time from penetration to ejaculation increased from an average of 0.6 minutes to 3.8 minutes in the medicated group and to just 1.1 minutes in the placebo group.

When these figures were adjusted to take account of any variations between the two groups, these showed that the treatment group were able to last 6.3 times longer after penetration when they used the spray. The placebo group lasted 1.7 times longer.

“Premature ejaculation can be a very distressing condition for men and can cause distress, frustration and make them avoid sexual intimacy” says lead researcher Professor W Wallace Dinsmore from the Royal Victoria Hospital, Belfast, UK.

The research team used the evidence-based definition of lifelong PE developed by the International Society for Sexual Medicine to select their study subjects.

This states that ejaculation occurs within about one minute of vaginal penetration in the majority of encounters.

“Because this definition was only launched in 2008, studies have yet to determine the prevalence of lifelong PE in the male population” says Professor Dinsmore.

“But previous research suggests that as many as 40 percent of men will experience premature ejaculation at some time in their lives,” the expert added.

The 300 men who took part in the phase three, multicentre, double-blind, randomised study had an average age of 35. The majority had used other treatments before, the most common being oral antidepressants.

After three months of treatment the researchers reported that 90 percent of the men in the treatment group were able to delay ejaculation for more than one minute following vaginal penetration, compared with 54 percent in the placebo group.

Seventy four percent of men in the treatment group managed to last more than two minutes before ejaculation, compared with 22 percent in the placebo group. 62 percent of men in the treatment group said their orgasms were ‘good’ or ‘very good’ after three months, compared with 20 percent before the study started.

The figures for the placebo group were slightly lower at the end than at the start. Also, a significantly higher percentage of the patients and partners in the treatment group reported improvements when it came to perceived control, personal distress, satisfaction with sexual intercourse and interpersonal difficulties.

“Our study shows that when the PSD502 spray was applied to the man’s penis five minutes before intercourse it improved both sexual performance and sexual satisfaction, which are key factors in treating premature ejaculation” says Professor Dinsmore.

“It was well tolerated by both patients and their partners, with no systemic side effects and a low incidence of localised effects and was rated favourably by the majority of users.

“We believe that this shows that PSD502 offers significant advantages over other therapies being developed for the treatment of premature ejaculation,” the researcher added. (ANI)

Vitamin B and folic acid ‘cut risk of age-related vision loss in women’

Washington, Feb 24 (ANI): Taking a combination of vitamins B6 and B12 and folic acid could reduce the risk of age-related sight problems in women, says a new study.

According to the report in the February 23 issue of Archives of Internal Medicine, one of the JAMA/Archives journals, age-related macular degeneration (AMD) is a leading cause of vision loss in older adults.

Treatment options exist for those with severe cases of the disease, but the only known prevention method is to avoid smoking.

To reach the conclusion, William G. Christen, Sc.D., of Brigham and Women’s Hospital and Harvard Medical School, Boston, and colleagues conducted a randomised, double blind clinical trial involving 5,442 women age 40 and older who already had heart disease or at least three risk factors.

Of these, 5,205 did not have AMD at the beginning of the study. In April 1998, these women were randomly assigned to take a placebo or a combination of folic acid (2.5 milligrams per day), pyridoxine hydrochloride (vitamin B6, 50 milligrams per day) and cyanocobalamin (vitamin B12, 1 milligram per day).

Participants continued the therapy through July 2005 and were tracked for the development of AMD through November 2005.

Over an average of 7.3 years of treatment and follow-up, 137 new cases of AMD were documented, including 70 cases that were visually significant (resulting in a visual acuity of 20/30 or worse).

Of these, 55 AMD cases, 26 visually significant, occurred in the 2,607 women in the active treatment group, whereas 82 of the 2,598 women in the placebo group developed AMD, 44 cases of which were visually significant.

Women taking the supplements had a 34 percent lower risk of any AMD and a 41 percent lower risk of visually significant AMD.

“The beneficial effect of treatment began to emerge at approximately two years of follow-up and persisted throughout the trial,” the authors write.

“The trial findings reported herein are the strongest evidence to date in support of a possible beneficial effect of folic acid and B vitamin supplements in AMD prevention,” they added. (ANI)